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Abstract: To manage myocardial recovery in patients with the HeartWare left ventricular assist
device (HVAD), we describe a minimally invasive approach ('decommissioning') that
involves disconnecting the driveline and occluding the outflow tract through a small left
thoracotomy incision leaving the device in situ, in conjunction with optimal medical
therapies and comprehensive assessment of left ventricular recovery. Nine patients (all
male, 37+/-12 years, all non-ischemic dilated cardiomyopathy) had an HVAD implanted
for 766+/-343 days. When left ventricular function improved to mild impairment by
echocardiography, patients underwent assessment at reduced flow (2578+/-148 to
1822+/-67 rpm) with documentation of compensated right heart hemodynamics and
ejection fraction 52+/-8%. Eight of nine patients underwent decommissioning, and 1
patient had a hybrid procedure of percutaneous occlusion of outflow graft and surgical
division of driveline. 2 patients died post operatively at 413 days (sepsis) and 810 days
(heart failure). In conclusion, in selected patients with non-ischemic dilated
cardiomyopathy a prolonged period of HVAD support in conjunction with heart failure
medications can lead to recovery of left ventricular function. Surgical decommissioning
is then an option to remove these patients from support. These patients are not
however 'cured' and remain at risk for future deterioration in ventricular function and
infections.
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Response to Reviewers: 
 
Dear Dr Slaughter, 
Thank-you for your further comments. Below are detailed responses to the reviewer’s 
comments.  
 
Reviewer #3: 
The authors have come back with some reasonable revisions. 
- They changed some references in the intro, but actually didn't read the articles they 
references. The recent Wever-Pinzon paper is based on debunking the Intermacs 
concept that the rate of recovery is 1.3%. This paper should not be used to continually 
reinforce the Intermacs competing outcomes data. 
Response: Apologies for the mistake. We have rephrased the opening 2 sentences to: 
‘Myocardial recovery in patients on left ventricular assist devices (LVAD) is well 
documented1,2, and in appropriately selected patients can be achieved in 24% of implants3. 
- With regards to rationale, the original question raised was not about the rationale for 
attempting to recover, but rather the rationale to decommission versus explant. They 
only really respond with a single statement with the natural orifice left behind. While 
this is a reasonable thought, others have put a titanium plug in to maintain the orifice as 
well. So, it is still unclear why decommissioning is better than other alternatives (besides 
the ease of doing it) 
Response: The rationale is now more clearly stated. It is the combination of the uncertain 
long term future (possible need for further device) and avoiding a complicated operation (full 
explant procedure). Furthermore, as a plug is likely needed to fill the apical deficit, the 
decommissioning procedure uses the device as its own plug. Thus, the ‘ease of doing it’ it 
certainly a significant factor. We now state ‘Thus, it has been proposed that remission rather 
than recovery is a more appropriate terminology when there is a risk of relapse in the future5. 
In that context, whether a definitive explant operation is needed initially should be 
questioned. A simpler operation, leaving the device in-situ, though occluding the outflow 
graft and severing the driveline using the device as its own apical plug will leave a natural 
orifice to re-implant a new device at a later date should that be needed.’ 
- with regards to timing, then, what is the average length of time that the patients were 
deemed recovered and then explanted. 
Response: Patients waited an average of 94+64 days from the low flow assessment until the 
decommissioning procedure. This wait was due to logistical reasons rather than a specific 
wait and see strategy, and if the wait was prolonged from the low flow assessment to the 
Response to Reviewers
operation we would repeat the echo before the operation to ensure no change in function 
(which was never observed) (page 6 last line going to page 7)  
- do they anticoagulate differently during their 5 days of low flow: 
Response: We do not change the anticoagulation during low flow. The standard 
anticoagulation protocol is INR target 2.7 and aspirin 300 mg daily. Of course, we would not 
do the assessment if the INR was subtherapeutic. This is stated on page 6, 2nd paragraph.  
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Abstract: 
To manage myocardial recovery in patients with the HeartWare left ventricular assist device 
(HVAD), we describe a minimally invasive approach (‘decommissioning’) that involves 
disconnecting the driveline and occluding the outflow tract through a small left thoracotomy 
incision leaving the device in situ, in conjunction with optimal medical therapies and 
comprehensive assessment of left ventricular recovery. Nine patients (all male, 37+12 years, 
all non-ischemic dilated cardiomyopathy) had an HVAD implanted for 766+343 days. When 
left ventricular function improved to mild impairment by echocardiography, patients 
underwent assessment at reduced flow (2578+148 to 1822+67 rpm) with documentation of 
compensated right heart hemodynamics and ejection fraction 52+8%. Eight of nine patients 
underwent decommissioning, and 1 patient had a hybrid procedure of percutaneous occlusion 
of outflow graft and surgical division of driveline. 2 patients died post operatively at 413 days 
(sepsis) and 810 days (heart failure). In conclusion, in selected patients with non-ischemic 
dilated cardiomyopathy a prolonged period of HVAD support in conjunction with heart 
failure medications can lead to recovery of left ventricular function. Surgical 
decommissioning is then an option to remove these patients from support. These patients are 
however not ‘cured’ and remain at risk for future deterioration in ventricular function and 
infections. 
Key Words: Recovery, left ventricular function, HeartWare left ventricular assist device 
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Introduction:  
Myocardial recovery in patients on left ventricular assist devices (LVAD) is well 
documented1,2, and in appropriately selected patients can be achieved in 24% of implants3. 
This potentially offers patients with a history of end-stage heart failure an alternative to long 
term left ventricular assist device (LVAD) support with its potential complications, or 
transplantation with its associated risks. Two issues with myocardial recovery on LVADs are 
clear: 1) that patients with recent onset non-ischemic dilated cardiomyopathy are more likely 
to recover than long standing non-ischemic cardiomyopathy2,3,4, or ischemic patients, and 2) 
there is a risk of future decline in ventricular function after recovery. For instance, in a recent 
report on recovery in the Interagency Registry for Mechanically Assisted Circulatory Support 
(INTERMACS) at 1 year post explantation 18 out of 21 patients were alive without further 
intervention, 1 had died and 2 had undergone transplantation3 Thus, it has been proposed that 
remission rather than recovery is a more appropriate terminology when there is a risk of 
relapse in the future5. In that context, whether a definitive explant operation is needed 
initially should be questioned. A simpler operation, leaving the device in-situ, though 
occluding the outflow graft and severing the driveline using the device as its own apical plug 
will leave a natural orifice to re-implant a new device at a later date should that be needed.  
 
In response to these issues we have developed a program of myocardial recovery with 
the HeartWare VAD (HVAD) that involves maximally tolerated standard heart failure 
therapies, monitoring of recovery for prolonged periods (usually well beyond 1 year), careful 
assessment of recovery at low HVAD flow rates, and then minimally invasive 
‘decommissioning’ surgery which involves leaving the HVAD in-situ, though occludes the 
outflow graft and cuts the driveline through a small left thoracotomy incision without the 
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need to arrest the heart.  In another patient a hybrid procedure of percutaneous outflow graft 
occlusion and surgical division of driveline was performed. We report the first 9 patients who 
have undergone this program who had devices implanted over a 7 year period.   
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Methods: 
Between July 2009 and Sept 2016, 170 adult patients underwent implantation of the 
HVAD at the Freeman Hospital as a bridge to transplant. The strategy as indicated in table 1 
was adopted to aid and assess myocardial recovery. In all patients flow rates of the device 
were set at time of implantation and set in part to allow some degree of aortic valve opening 
detectable by echocardiography. Patient details of those that were successfully 
decommissioned are presented in table 2. All patients were male. Eight of the nine patients 
were on pre-operative inotropes, 2 had intra-aortic balloon pumps, and 2 patients were on 
arterio-venous extracorporeal membrane oxygenation. Diagnosis was established by a 
combination of clinical presentation, family history, and myocardial histology. This study 
adhered to the terms of the United Kingdom Data and Protection Act and Freedom of 
Information Act, and was approved to obtain confidential information by the local Caldicott 
Guardian. 
Echocardiograms were performed by experienced echocardiographers. Left 
ventricular dimensions were measured from parasternal long axis views. As left ventricular 
function is difficult to quantify in patients with the HeartWare device causing difficulty in 
obtaining apical windows, a scale of left ventricular function was used from 1-4 (1 = normal, 
2 = mild, 3 = moderate, and 4 = severe impairment). As this was a semi-quantitative 
measurement, we also obtained computed tomography (CT) angiograms for measurement of 
left ventricular end-diastolic volume and ejection fraction for the final assessment pre-
decommissioning at low flow. Right ventricular function with the echocardiograms were also 
measured using a semi-quantitative scale from 1-6 (1 = normal, 2 = mild, 3 = mild-moderate, 
4 = moderate, 5 = moderate-severe, and 6 = severe). Right heart catheterization for 
measurement of right and left heart fillings pressures and thermodilution cardiac output was 
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performed, and a cardiopulmonary stress test for determination of peak exercise oxygen 
consumption.  
Surgical Decommissioning: In order to keep the surgical trauma to the recovered 
myocardium to a minimum, a new surgical strategy was introduced6, not to remove the pump 
at all, but rather use the pump as a “plug”. A 5 cm antero-lateral thoracotomy was performed 
via the sixth intercostal space with the patient in the supine position. This small incision 
allows exposure of the HVAD pump, and removal of the 3 plastic rings covering the outflow 
graft. The outflow graft was exposed, encircled and divided. The drive line was than exposed 
at the lower end of the xiphoid or were it is brought out of the thoracic cavity, and divided 
(figure 1). In most cases it was feasible to pull out the driveline remnant distally at the exit 
site. In some cases an additional incision was required to allow removal. In the ninth case, a 
hybrid procedure was performed with percutaneous closure of the outflow graft and surgical 
division of the driveline. This was performed because the outflow graft could not be reached 
through the thoracotomy incision. Anticoagulation with warfarin was continued for an 
internationalised normalised ratio of 2 – 2.5 following decommissioning, and antiplatelets 
discontinued.  
 
Data Analysis: Data are presented as mean + standard deviation. Survival curves 
were composed using SPSS (version 22) and groups compared using the Tarone Ware test.  
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Results:  
Nine patients have been surgically decommissioned from this cohort, which 
represents 5.2 % of the total number, and 10.0 % of those patients with non-ischaemic dilated 
cardiomyopathy (mean age 37+12, range 19 – 53 years; all male). Four other patients in the 
total cohort who are not included in this report had only partial myocardial recovery but 
serious complications requiring full VAD explantation: 2 with prior myocardial infarction 
(one with recurrent haemorrhage and one with adverse social conditions precluding discharge 
from hospital), one patient with idiopathic dilated cardiomyopathy and resistant VAD-related 
pseudomonas sepsis, and another with idiopathic dilated cardiomyopathy and non 
compliance-induced device thrombosis. Only one of these partially recovered patients was a 
long term survivor.  
Mean duration of support was 766+343 (range 205 – 1145) days and mean follow up 
post decommissioning was 695+341 (range 330 – 1359) days. The mean hemodynamics of 
the successful low flow assessments are presented in table 3. The standard anticoagulation 
regimen was not changed during the low flow assessments (warfarin target INR 2.7 and 
aspirin 300 mg daily). On average there were 1.8+1.0 of these assessments for each patient, 
repeated until patients had acceptable hemodynamics and left and right ventricular function 
on low flow. Criteria to proceed with surgical decommissioning were after 5 days of low flow 
investigations: unchanged left and right ventricular function by echocardiogram (with at 
worst mild left and right ventricular function), left ventricular ejection fraction > 40% on 
gated cardiac CT, and pulmonary arterial wedge pressure < 15 mm Hg and cardiac index > 
1.8 ml/min/m2 on low flow.  Reasons for not passing the low flow assessments were as 
follows:  low cardiac output N=1, right ventricular function N=2, left ventricular function 
N=1, and abnormal pulmonary arterial wedge pressure N=3. Of note, all but 1 patient had 
recent onset heart failure. The mean time from the low flow assessment to the 
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decommissioning procedure was 94+64 days. Mean post-operative length of stay was 6+1 
days. 
One patient died at 413 days post decommissioning due to sepsis. This was a patient 
with poor mobility due to Becker’s muscular dystrophy, obesity and previous methicillin 
sensitive staphylococcus aureus colonisation of his driveline who had been treated with long 
term suppression with flucloxacillin before the decommissioning. The final admission with 
sepsis was probably precipitated in part by non-compliance with the antibiotic regimen. 
Another patient died at 810 days post decommissioning with heart failure. One patient has 
had a complete VAD explant since the initial decommissioning because of recurrent sepsis. 
This patient and the remaining 6 patients are well and free from symptoms of heart failure.  
 
Serial Echocardiograms: Results of serial echocardiograms pre and post 
decommissioning are presented in figure 2. On support, over time there are reductions in left 
ventricular end-diastolic dimensions, end-systolic dimensions, and improvement in left 
ventricular function grade. Of note it takes approximately 700 days for left ventricular 
function to improve to the level of mild impairment. Right ventricular function improves to 
mild to moderately impaired from between moderate and moderate to severe impairment at 
the time of implant. Following decommissioning, there is reduction in left ventricular 
function again, so that after 1 year post decommissioning, left ventricular function on average 
is between mild and moderate dysfunction. In the 7 survivors, 2 have normal left ventricular 
function, 3 mild, 1 moderate and 1 severe dysfunction. Left ventricular dimensions do not 
change, and right ventricular function remains between mild to moderately impaired.  
Survival of the decommissioned cohort from the time of VAD implant was compared 
to all other HVAD patients implanted at this centre. For the non-decommissioned HVAD 
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cohort an event included death on the device, and death after transplant. Survival was 
significantly better in the decommissioned group compared to the non-decommissioned 
patients (figure 3).  
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Discussion: 
We demonstrate in this study that in patients with predominantly recent onset, non 
ischaemic cardiomyopathy after a significant period of support with the HVAD on maximal 
medical therapies, careful low flow assessments and minimally invasive surgery leaving the 
HVAD in-situ but disconnected, that recovered patients can be safely removed from device 
support. The immediate surgical risk is low, but there are potential problems with long term 
follow-up with potential sepsis and deteriorating left ventricular function.  
 
Minimally invasive surgery to reduce risk: Surgery to explant the device can carry 
significant risk. Birks and colleagues reported that 3 of 23 HeartMate II patients explanted 
died peri-operatively7. Frazier and colleagues8 have recently reported a modified technique to 
explant the HeartMate II device that involves leaving the inflow cannula in place and 
removing the rest of the device. Our technique with the HVAD takes this evolution one step 
further and retains the device in-situ. An alternative is a percutaneous approach using 
vascular plugs to close the outflow graft9, which we have also used in 1 patient. To-date our 
approach has not led to any immediate post operative adverse events, though there are 
potential long term problems. All patients have been left on an empiric dose of warfarin 
anticoagulation to maintain an INR of 2 – 2.5.  
 
Recovery with the HVAD: The assessment of recovery with the HVAD as described 
shares a lot of the attributes described with other devices7,10,11,12. There is a period of 
unloading and when function appears to improve assessments are performed at low flows. 
Compared to the study from Birks and colleagues with the Heartmate 2 device the 
development of recovery with increasing function and reduced dimensions in the current 
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study is significantly slower7. In their study the majority of patients achieved normal ejection 
fractions by 4-5 months. Other groups have shown the same phenomenon. Dandel et al10 have 
shown in a group of patients with a variety of LVADs (though not the HVAD) that the mean 
duration of support to allow explantation was 4.9+2.8 months. Drakos et al12 have likewise 
shown that the largest increase in ejection fraction on support was at 270 days. The reasons 
for this are unclear: there are 2 possibilities – 1) that the HVAD has intrinsic less unloading 
properties than other VADs, and/or 2) that our setting of aortic valve opening in all patients 
leads to less unloading. We have previously reported that with the HVAD13 at 200 days of 
support the left ventricular end-diastolic dimension reduces from 7.2+1.0 to 6.9+1.2 cm (at an 
average of 2522+174 revolutions per minute). In other studies using other continuous flow 
devices there is apparently greater unloading. For instance, in a comparison of pulsatile and 
continuous flow unloading with the HeartMate II device, Kato et al14 have shown that after a 
median of 100 days support left ventricular end-diastolic dimension reduces from 6.8+1.1 to 
5.6+1.5. Likewise, Maybaum et al15 have shown greater unloading of the left ventricle in a 
study involving predominantly the Heartmate 2 device. However, Gupta et al16 with the 
HVAD have shown at 100 days that left ventricular end-diastolic dimension reduces from 
7.1+1.3 to 6.1+1.4 cm, though at a higher mean pump speed of 2693+139 rpm, specifically 
set so that the aortic valve was closed. Thus, the issue of slow left ventricular remodelling 
seems to be an issue of the HVAD settings rather than specifically related to the type of 
device. We do not know if allowing the aortic valve to open from implantation has benefits in 
terms of long term recovery. We do however know that an aortic valve that opens is likely to 
develop aortic regurgitation and thromboembolic events17,18. 
 
Long term outcomes: The long term outcomes of these patients compare favourably 
to those previously reported with the Heartmate 2 device. Birks et al7 have reported an 
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approximate 50% survival in recovered explanted patients at 750 days, which compares to 
approximately 50% survival at 2000 days in the current study (figure 3). One patient has died 
of sepsis and one of heart failure. There is potential for future deterioration in left ventricular 
function despite the optimal medical treatments, and sepsis, and so these patients cannot be 
considered cured5. Dandel et al have reported a 66% 5 year freedom for heart failure10. In a 
group of 27 explanted patients, Frazier et al8 have reported 1 transplant, 1 device 
reimplantation, 3 strokes and 2 deaths for a mean survival time post explant of 1097+926 
days. Leaving the device in situ leaves a natural conduit through which to place a new device 
should that be needed in the future. An alternative is repair of the apical defect, though we do 
not know if this has a beneficial impact on left ventricular function. Ideally, to minimise long 
term infection risk those patients who have had systemic infections while the device is 
operating should probably have a full explant procedure. Our patient who died of sepsis was a 
high risk patient for both an explant procedure (obesity with Becker’s muscular dystrophy) 
but also at high risk for infection given history of colonisation with methicillin sensitive 
Staphylococcus aureus, so posed a difficult real world dilemma.    
 
Conclusions: In selected patients with end-stage heart failure and non-ischemic 
dilated cardiomyopathy supported with the HVAD a prolonged period of device support in 
conjunction with optimal heart failure medications can lead to recovery of left ventricular 
function. Surgical decommissioning is then a practical option to remove these patients from 
support without the need for extensive surgery. Nevertheless, there is a risk of deterioration in 
left ventricular function and recurrence of heart failure in the long term.  
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Figure Legends: 
Figure 1. Chest X rays of the same patient immediately after VAD implant (left), and then 
post surgical decommissioning (right). Arrows point to the driveline. Post decommissioning 
the VAD is in situ, and the arrow indicates were the driveline has been cut. The contrast on 
the images has been increased so that the driveline is more easily seen.  
 
Figure 2: Serial echocardiograms before decommissioning (left column) and post 
decommissioning (right). A. and B. left ventricular end-diastolic (LVEDD) and end-systolic 
dimensions (LVESD); C. and D. left ventricular function on a graded visual scale from 1-4 
with 1 being normal and 4 severe; D. and E. right ventricular function on a graded visual 
scale from 1-6 with 1 being normal and 6 severe. At the bottom of each column is the number 
of scans available for each time point.  
 
Figure 3: Survival of decommissioned patients (grey line) with all other HVAD patients 
(black). Survival is significantly better in the decommissioned patients (P<0.01).  
 
Table 1: 
Strategy for Managing and Assessing Potential Patients for Decommissioning: 
1. Maximally tolerated standard heart failure therapies. 
2. Serial echocardiograms until LV function rated as mild. 
3. 5 Day low flow assessment. 
4. Day 1: Echocardiogram on full flow and then reduced flow. If no change in function 
proceed with complete assessment. 
5. Day 4: Right heart catheterisation and cardiopulmonary stress tests on low flow. 
6. Day 5: CT angiogram and final echocardiogram on low flow.  
7. Surgical Decommissioning if acceptable haemodynamics and no deterioration in 
echocardiogram at low flow.  
8. Discharge on pre-operative maximally tolerated heart failure therapies. No antiplatelets. 
Warfarin for INR target range 2 – 2.5 
 
 
Table 1
Table 2: Patient Characteristics: 
Patient Age Diagnosis Duration of 
Heart Failure 
Days on  
Support 
Intermacs 
Class 
Medications: 
(daily dose) 
1 22 Familial Dilated 
Cardiomyopathy 
1st Admission 940 2 Bisoprolol 10 mg 
Lisinopril 20 mg 
Spiro. 25 mg 
Ivabradine 10 mg 
2 25 Familial Dilated 
Cardiomyopathy 
1st Admission 837 1 Bisoprolol 10 mg 
Lisinopril 5 mg 
Eplerenone 25 mg 
Ivabradine 10 mg 
3 53 Idiopathic 
Dilated 
Cardiomyopathy 
1 year 1145 4 Bisoprolol 10 mg 
Lisinopril 15 mg 
Spiro. 25 mg 
Ivabradine 10 mg 
4 19 Familial Dilated 
Cardiomyopathy 
1st admission 917 2 Bisoprolol 10 mg 
Lisinopril 20 mg 
Eplerenone 25 mg 
5 39 Sarcoidosis 1st Admission 1078 1 Bisoprolol 7.5 mg 
Candesartan 4 mg 
Prednisolone 15 
mg 
6 42 Becker’s 
Muscular 
Dystrophy 
Cardiomyopathy 
1st Admission 861 1 Bisoprolol 10 mg 
Lisinopril 20 mg 
Ivabradine 10 mg 
7 44 Idiopathic 
Dilated 
Cardiomyopathy 
1st Admission 205 1 Bisoprolol 2.5 mg 
Lisinopril 2.5 mg 
8 35 Idiopathic 
Dilated 
Cardiomyopathy 
1st Admission 646 3 Bisoprolol 7.5 mg  
Hydralazine + 
Nitrates 
9 51 Acute 
myocarditis 
1st Admission 225 1 Bisoprolol 5mg  
Lisinpopril 15 mg  
Spiro: spironolactone. 
 
Table 2
Table 3: 
Pre-Decommissioning Low Flow Investigations: 
Baseline Flow Rate (rpm)  2578+148 
Reduced Flow Rate (rpm)  1822+67 
Low flow haemodynamics: Heart Rate (beats/min) 73+9 
 Systolic Blood Pressure (mm Hg) 101+10 
 Diastolic Blood Pressure (mm Hg) 61+12 
 Right Atrial Pressure (mm Hg) 4+3 
 Pulmonary Artery Systolic Pressure (mm Hg) 21+6 
 Pulmonary Artery Mean Pressure (mm Hg) 15+4 
 Pulmonary Arterial Wedge Pressure (mm Hg) 9+3 
 Cardiac Index (L/min/m2) 2.3+0.4 
 Pulmonary Arterial Oxygen Saturation (%) 68+5 
 Peak Exercise Oxygen Consumption (mL/kg/min) 18.0+4.6 
 CT Ejection Fraction (%) 52+8 
 CT End-Diastolic Volume (mL) 154+61 
 
Table 3
Figure 1 Click here to download Figure Xray figure2.tif 
Figure 2 Click here to download Figure Echo figure_updated Sept 2016.tif 
Figure 3 Click here to download Figure Survival Figure_rev.tif 
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Abstract: 
To manage myocardial recovery in patients with the HeartWare left ventricular assist device 
(HVAD), we describe a minimally invasive approach (‘decommissioning’) that involves 
disconnecting the driveline and occluding the outflow tract through a small left thoracotomy 
incision leaving the device in situ, in conjunction with optimal medical therapies and 
comprehensive assessment of left ventricular recovery. Nine patients (all male, 37+12 years, 
all non-ischemic dilated cardiomyopathy) had an HVAD implanted for 766+343 days. When 
left ventricular function improved to mild impairment by echocardiography, patients 
underwent assessment at reduced flow (2578+148 to 1822+67 rpm) with documentation of 
compensated right heart hemodynamics and ejection fraction 52+8%. Eight of nine patients 
underwent decommissioning, and 1 patient had a hybrid procedure of percutaneous occlusion 
of outflow graft and surgical division of driveline. 2 patients died post operatively at 413 days 
(sepsis) and 810 days (heart failure). In conclusion, in selected patients with non-ischemic 
dilated cardiomyopathy a prolonged period of HVAD support in conjunction with heart 
failure medications can lead to recovery of left ventricular function. Surgical 
decommissioning is then an option to remove these patients from support. These patients are 
however not ‘cured’ and remain at risk for future deterioration in ventricular function and 
infections. 
Key Words: Recovery, left ventricular function, HeartWare left ventricular assist device 
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Introduction:  
MWhereas myocardial recovery in patients on left ventricular assist devices (LVAD) 
is well documented1,2, overall it is relatively rare, occurring in 1.3% of implantsand in 
appropriately selected patients can be achieved in 24% of implants3. Nevertheless, tThis 
potentially offers patients with a history of end-stage heart failure an alternative to long term 
left ventricular assist device (LVAD) support with its potential complications, or 
transplantation with its associated risks. Despite this, 2Two issues with myocardial recovery 
on LVADs are clear: 1) that patients with recent onset non-ischemic dilated cardiomyopathy 
are more likely to recover than long standing non-ischemic cardiomyopathy2,3,4, or ischemic 
patients, and 2) there is a risk of future decline in ventricular function after recovery. For 
instance, in a recent report on recovery in the Interagency Registry for Mechanically Assisted 
Circulatory Support (INTERMACS) at 1 year post explantation 18 out of 21 patients were 
alive without further intervention, 1 had died and 2 had undergone transplantation3 Thus, it 
has been proposed that remission rather than recovery is a more appropriate terminology 
when there is a risk of relapse in the future5. In that context, whether a definitive explant 
operation is needed initially should be questioned. A simpler operation, Lleaving the device 
in-situ, though occluding the outflow graft and severing the driveline using the device as its 
own apical plug will leave a natural orifice to re-implant a new device at a later date should 
that be needed.  
 
In response to these issues we have developed a program of myocardial recovery with 
the HeartWare VAD (HVAD) that involves maximally tolerated standard heart failure 
therapies, monitoring of recovery for prolonged periods (usually well beyond 1 year), careful 
assessment of recovery at low HVAD flow rates, and then minimally invasive 
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‘decommissioning’ surgery which involves leaving the HVAD in-situ, though occludes the 
outflow graft and cuts the driveline through a small left thoracotomy incision without the 
need to arrest the heart.  In another patient a hybrid procedure of percutaneous outflow graft 
occlusion and surgical division of driveline was performed. We report the first 9 patients who 
have undergone this program who had devices implanted over a 7 year period.   
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Methods: 
Between July 2009 and Sept 2016, 170 adult patients underwent implantation of the 
HVAD at the Freeman Hospital as a bridge to transplant. The strategy as indicated in table 1 
was adopted to aid and assess myocardial recovery. In all patients flow rates of the device 
were set at time of implantation and set in part to allow some degree of aortic valve opening 
detectable by echocardiography. Patient details of those that were successfully 
decommissioned are presented in table 2. All patients were male. Eight of the nine patients 
were on pre-operative inotropes, 2 had intra-aortic balloon pumps, and 2 patients were on 
arterio-venous extracorporeal membrane oxygenation. Diagnosis was established by a 
combination of clinical presentation, family history, and myocardial histology. This study 
adhered to the terms of the United Kingdom Data and Protection Act and Freedom of 
Information Act, and was approved to obtain confidential information by the local Caldicott 
Guardian. 
Echocardiograms were performed by experienced echocardiographers. Left 
ventricular dimensions were measured from parasternal long axis views. As left ventricular 
function is difficult to quantify in patients with the HeartWare device causing difficulty in 
obtaining apical windows, a scale of left ventricular function was used from 1-4 (1 = normal, 
2 = mild, 3 = moderate, and 4 = severe impairment). As this was a semi-quantitative 
measurement, we also obtained computed tomography (CT) angiograms for measurement of 
left ventricular end-diastolic volume and ejection fraction for the final assessment pre-
decommissioning at low flow. Right ventricular function with the echocardiograms were also 
measured using a semi-quantitative scale from 1-6 (1 = normal, 2 = mild, 3 = mild-moderate, 
4 = moderate, 5 = moderate-severe, and 6 = severe). Right heart catheterization for 
measurement of right and left heart fillings pressures and thermodilution cardiac output was 
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performed, and a cardiopulmonary stress test for determination of peak exercise oxygen 
consumption.  
Surgical Decommissioning: In order to keep the surgical trauma to the recovered 
myocardium to a minimum, a new surgical strategy was introduced6, not to remove the pump 
at all, but rather use the pump as a “plug”. A 5 cm antero-lateral thoracotomy was performed 
via the sixth intercostal space with the patient in the supine position. This small incision 
allows exposure of the HVAD pump, and removal of the 3 plastic rings covering the outflow 
graft. The outflow graft was exposed, encircled and divided. The drive line was than exposed 
at the lower end of the xiphoid or were it is brought out of the thoracic cavity, and divided 
(figure 1). In most cases it was feasible to pull out the driveline remnant distally at the exit 
site. In some cases an additional incision was required to allow removal. In the ninth case, a 
hybrid procedure was performed with percutaneous closure of the outflow graft and surgical 
division of the driveline. This was performed because the outflow graft could not be reached 
through the thoracotomy incision. Anticoagulation with warfarin was continued for an 
internationalised normalised ratio of 2 – 2.5 following decommissioning, and antiplatelets 
discontinued.  
 
Data Analysis: Data are presented as mean + standard deviation. Survival curves 
were composed using SPSS (version 22) and groups compared using the Tarone Ware test.  
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Results:  
Nine patients have been surgically decommissioned from this cohort, which 
represents 5.2 % of the total number, and 10.0 % of those patients with non-ischaemic dilated 
cardiomyopathy (mean age 37+12, range 19 – 53 years; all male). Four other patients in the 
total cohort who are not included in this report had only partial myocardial recovery but 
serious complications requiring full VAD explantation: 2 with prior myocardial infarction 
(one with recurrent haemorrhage and one with adverse social conditions precluding discharge 
from hospital), one patient with idiopathic dilated cardiomyopathy and resistant VAD-related 
pseudomonas sepsis, and another with idiopathic dilated cardiomyopathy and non 
compliance-induced device thrombosis. Only one of these partially recovered patients was a 
long term survivor.  
Mean duration of support was 766+343 (range 205 – 1145) days and mean follow up 
post decommissioning was 695+341 (range 330 – 1359) days. The mean hemodynamics of 
the successful low flow assessments are presented in table 3. The standard anticoagulation 
regimen was not changed during the low flow assessments (warfarin target INR 2.7 and 
aspirin 300 mg daily). On average there were 1.8+1.0 of these assessments for each patient, 
repeated until patients had acceptable hemodynamics and left and right ventricular function 
on low flow. Criteria to proceed with surgical decommissioning were after 5 days of low flow 
investigations: unchanged left and right ventricular function by echocardiogram (with at 
worst mild left and right ventricular function), left ventricular ejection fraction > 40% on 
gated cardiac CT, and pulmonary arterial wedge pressure < 15 mm Hg and cardiac index > 
1.8 ml/min/m2 on low flow.  Reasons for not passing the low flow assessments were as 
follows:  low cardiac output N=1, right ventricular function N=2, left ventricular function 
N=1, and abnormal pulmonary arterial wedge pressure N=3. Of note, all but 1 patient had 
recent onset heart failure. The mean time from the low flow assessment to the 
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decommissioning procedure was 94+64 days. Mean post-operative length of stay was 6+1 
days. 
One patient died at 413 days post decommissioning due to sepsis. This was a patient 
with poor mobility due to Becker’s muscular dystrophy, obesity and previous methicillin 
sensitive staphylococcus aureus colonisation of his driveline who had been treated with long 
term suppression with flucloxacillin before the decommissioning. The final admission with 
sepsis was probably precipitated in part by non-compliance with the antibiotic regimen. 
Another patient died at 810 days post decommissioning with heart failure. One patient has 
had a complete VAD explant since the initial decommissioning because of recurrent sepsis. 
This patient and the remaining 6 patients are well and free from symptoms of heart failure.  
 
Serial Echocardiograms: Results of serial echocardiograms pre and post 
decommissioning are presented in figure 2. On support, over time there are reductions in left 
ventricular end-diastolic dimensions, end-systolic dimensions, and improvement in left 
ventricular function grade. Of note it takes approximately 700 days for left ventricular 
function to improve to the level of mild impairment. Right ventricular function improves to 
mild to moderately impaired from between moderate and moderate to severe impairment at 
the time of implant. Following decommissioning, there is reduction in left ventricular 
function again, so that after 1 year post decommissioning, left ventricular function on average 
is between mild and moderate dysfunction. In the 7 survivors, 2 have normal left ventricular 
function, 3 mild, 1 moderate and 1 severe dysfunction. Left ventricular dimensions do not 
change, and right ventricular function remains between mild to moderately impaired.  
Survival of the decommissioned cohort from the time of VAD implant was compared 
to all other HVAD patients implanted at this centre. For the non-decommissioned HVAD 
Formatted: Underline
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cohort an event included death on the device, and death after transplant. Survival was 
significantly better in the decommissioned group compared to the non-decommissioned 
patients (figure 3).  
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Discussion: 
We demonstrate in this study that in patients with predominantly recent onset, non 
ischaemic cardiomyopathy after a significant period of support with the HVAD on maximal 
medical therapies, careful low flow assessments and minimally invasive surgery leaving the 
HVAD in-situ but disconnected, that recovered patients can be safely removed from device 
support. The immediate surgical risk is low, but there are potential problems with long term 
follow-up with potential sepsis and deteriorating left ventricular function.  
 
Minimally invasive surgery to reduce risk: Surgery to explant the device can carry 
significant risk. Birks and colleagues reported that 3 of 23 HeartMate II patients explanted 
died peri-operatively7. Frazier and colleagues8 have recently reported a modified technique to 
explant the HeartMate II device that involves leaving the inflow cannula in place and 
removing the rest of the device. Our technique with the HVAD takes this evolution one step 
further and retains the device in-situ. An alternative is a percutaneous approach using 
vascular plugs to close the outflow graft9, which we have also used in 1 patient. To-date our 
approach has not led to any immediate post operative adverse events, though there are 
potential long term problems. All patients have been left on an empiric dose of warfarin 
anticoagulation to maintain an INR of 2 – 2.5.  
 
Recovery with the HVAD: The assessment of recovery with the HVAD as described 
shares a lot of the attributes described with other devices7,10,11,12. There is a period of 
unloading and when function appears to improve assessments are performed at low flows. 
Compared to the study from Birks and colleagues with the Heartmate 2 device the 
development of recovery with increasing function and reduced dimensions in the current 
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study is significantly slower7. In their study the majority of patients achieved normal ejection 
fractions by 4-5 months. Other groups have shown the same phenomenon. Dandel et al10 have 
shown in a group of patients with a variety of LVADs (though not the HVAD) that the mean 
duration of support to allow explantation was 4.9+2.8 months. Drakos et al12 have likewise 
shown that the largest increase in ejection fraction on support was at 270 days. The reasons 
for this are unclear: there are 2 possibilities – 1) that the HVAD has intrinsic less unloading 
properties than other VADs, and/or 2) that our setting of aortic valve opening in all patients 
leads to less unloading. We have previously reported that with the HVAD13 at 200 days of 
support the left ventricular end-diastolic dimension reduces from 7.2+1.0 to 6.9+1.2 cm (at an 
average of 2522+174 revolutions per minute). In other studies using other continuous flow 
devices there is apparently greater unloading. For instance, in a comparison of pulsatile and 
continuous flow unloading with the HeartMate II device, Kato et al14 have shown that after a 
median of 100 days support left ventricular end-diastolic dimension reduces from 6.8+1.1 to 
5.6+1.5. Likewise, Maybaum et al15 have shown greater unloading of the left ventricle in a 
study involving predominantly the Heartmate 2 device. However, Gupta et al16 with the 
HVAD have shown at 100 days that left ventricular end-diastolic dimension reduces from 
7.1+1.3 to 6.1+1.4 cm, though at a higher mean pump speed of 2693+139 rpm, specifically 
set so that the aortic valve was closed. Thus, the issue of slow left ventricular remodelling 
seems to be an issue of the HVAD settings rather than specifically related to the type of 
device. We do not know if allowing the aortic valve to open from implantation has benefits in 
terms of long term recovery. We do however know that an aortic valve that opens is likely to 
develop aortic regurgitation and thromboembolic events17,18. 
 
Long term outcomes: The long term outcomes of these patients compare favourably 
to those previously reported with the Heartmate 2 device. Birks et al7 have reported an 
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approximate 50% survival in recovered explanted patients at 750 days, which compares to 
approximately 50% survival at 2000 days in the current study (figure 3). One patient has died 
of sepsis and one of heart failure. There is potential for future deterioration in left ventricular 
function despite the optimal medical treatments, and sepsis, and so these patients cannot be 
considered cured5. Dandel et al have reported a 66% 5 year freedom for heart failure10. In a 
group of 27 explanted patients, Frazier et al8 have reported 1 transplant, 1 device 
reimplantation, 3 strokes and 2 deaths for a mean survival time post explant of 1097+926 
days. Leaving the device in situ leaves a natural conduit through which to place a new device 
should that be needed in the future. An alternative is repair of the apical defect, though we do 
not know if this has a beneficial impact on left ventricular function. Ideally, to minimise long 
term infection risk those patients who have had systemic infections while the device is 
operating should probably have a full explant procedure. Our patient who died of sepsis was a 
high risk patient for both an explant procedure (obesity with Becker’s muscular dystrophy) 
but also at high risk for infection given history of colonisation with methicillin sensitive 
Staphylococcus aureus, so posed a difficult real world dilemma.    
 
Conclusions: In selected patients with end-stage heart failure and non-ischemic 
dilated cardiomyopathy supported with the HVAD a prolonged period of device support in 
conjunction with optimal heart failure medications can lead to recovery of left ventricular 
function. Surgical decommissioning is then a practical option to remove these patients from 
support without the need for extensive surgery. Nevertheless, there is a risk of deterioration in 
left ventricular function and recurrence of heart failure in the long term.  
 
 
12 
  ASAIO-16310 R2 
References: 
1. Birks EJ, George RS, Hedger M, et al. Reversal of severe heart failure with a 
continuous-flow left ventricular assist device and pharmacological therapy: a 
prospective study. Circulation. 123: 381-390, 2011. 
2. Simon MA, Kormos RL, Murali S, et al. Myocardial Recovery Using Ventricular 
Assist Devices Prevalence, Clinical Characteristics, and Outcomes. Circulation. 
112[suppl I]: I-32–I-36, 2005. 
3. Wever-Pinzon O, Drakos SG, McKellar SH, et al. Cardiac Recovery During Long-
Term Left Ventricular Assist Device Support. J Am Coll Cardiol. 2016 Oct 
4;68(14):1540-53 
4. Boehmer JP, Starling RC, Cooper LT, et al; IMAC Investigators. Left ventricular 
assist device support and myocardial recovery in recent onset cardiomyopathy. J Card 
Fail. 18: 755-61, 2012. 
5. Mann DL, Barger PM, Burkhoff D. Myocardial recovery and the failing heart. Myth, 
magic or molecular target. J Am Coll Cardiol 60: 2465-72, 2012. 
6. Sajjad M, Butt T, Oezalp F, et al. An alternative approach to explantation and 
exchange of the HeartWare left ventricular assist device. Eur J Cardiothorac Surg. 43: 
1247-50, 2013. 
7. Birks EJ, George RS, Hedger M, et al. Reversal of severe heart failure with a 
continuous-flow left ventricular assist device and pharmacological therapy: a 
prospective study. Circulation. 123: 381-390, 2011. 
8. Frazier OH, Baldwin AC, Demirozu ZT, et al. Ventricular reconditioning and pump 
explantation in patients supported by continuous-flow left ventricular assist devices. J 
Heart Lung Transplant. 34: 766-72, 2015. 
13 
  ASAIO-16310 R2 
9. Pettit SJ, Shapiro LM, Lewis C, Parameshwar JK, Tsui SS. Percutaneous withdrawal 
of HeartWare HVAD left ventricular assist device support. J Heart Lung Transplant. 
34: 990-2, 2015. 
10. Dandel M, Weng Y, Siniawski H, et al. Prediction of cardiac stability after weaning 
from left ventricular assist devices in patients with idiopathic dilated cardiomyopathy. 
Circulation. 118: S94-105, 2008. 
11. Dandel M, Weng Y, Siniawski H, et al. Heart failure reversal by ventricular unloading 
in patients with chronic cardiomyopathy: criteria for weaning from ventricular assist 
devices. Eur Heart J. 32: 1148-60, 2011. 
12. Drakos SG, Wever-Pinzon O, Selzman CH et al. Magnitude and time course of 
changes induced by continuous-flow left ventricular assist device unloading in 
chronic heart failure: insights into cardiac recovery. J Am Coll Cardiol. 2013 May 
14;61(19):1985-94 
13. McDiarmid A, Gordon B, Wrightson N, et al. Hemodynamic, echocardiographic, and 
exercise-related effects of the HeartWare left ventricular assist device in advanced 
heart failure. Congest Heart Fail. 19: 11-5, 2013. 
14. Kato TS, Chokshi A, Singh P, et al. Effects of continuous-flow versus pulsatile-flow 
left ventricular assist devices on myocardial unloading and remodeling. Circ Heart 
Fail. 4: 546-53, 2011. 
15. Maybaum S, Mancini D, Xydas S, et al Cardiac improvement during mechanical 
circulatory support: a prospective multicenter study of the LVAD Working Group. 
Circulation. 115: 2497-505, 2007. 
16. Gupta S, Woldendorp K, Muthiah K, et al. Normalisation of haemodynamics in 
patients with end-stage heart failure with continuous-flow left ventricular assist device 
therapy. Heart Lung Circ. 23: 963-9, 2014. 
14 
  ASAIO-16310 R2 
17. Bhagra S, Bhagra C, Özalp F, et al. Development of de novo aortic valve 
incompetence in patients with the continuous-flow HeartWare ventricular assist 
device. J Heart Lung Transplant. 2016 Mar;35(3):312-9. 
18. Dobarro D, Urban M, Booth K, et al. Impact of aortic valve closure on adverse events 
and outcomes with the HeartWare ventricular assist device. J Heart Lung Transplant. 
2016 Aug 18. pii: S1053-2498(16)30287-X. 
  
15 
  ASAIO-16310 R2 
Figure Legends: 
Figure 1. Chest X rays of the same patient immediately after VAD implant (left), and then 
post surgical decommissioning (right). Arrows point to the driveline. Post decommissioning 
the VAD is in situ, and the arrow indicates were the driveline has been cut. The contrast on 
the images has been increased so that the driveline is more easily seen.  
 
Figure 2: Serial echocardiograms before decommissioning (left column) and post 
decommissioning (right). A. and B. left ventricular end-diastolic (LVEDD) and end-systolic 
dimensions (LVESD); C. and D. left ventricular function on a graded visual scale from 1-4 
with 1 being normal and 4 severe; D. and E. right ventricular function on a graded visual 
scale from 1-6 with 1 being normal and 6 severe. At the bottom of each column is the number 
of scans available for each time point.  
 
Figure 3: Survival of decommissioned patients (grey line) with all other HVAD patients 
(black). Survival is significantly better in the decommissioned patients (P<0.01).  
 
